| 1. |
|
|
| 2. |
- Ahrens, J, et al.
(författare)
-
First measurement of the helicity-dependent (gamma)over-right-arrow(p)over-right-arrow -> p eta differential cross-section
- 2003
-
Ingår i: European Physical Journal A. Hadrons and Nuclei. - : Springer Science and Business Media LLC. - 1434-6001. ; 17:2, s. 241-244
-
Tidskriftsartikel (refereegranskat)abstract
- The helicity dependence of the (γ) over right arrow(p) over right arrow -+ peta reaction has been measured for the first time at a center-of-mass angle theta(eta)*= 70degrees in the photon energy range from 780 MeV to 790 MeV. The experiment, performed at the Mainz microtron MAMI, used a 4pi-detector system, a circularly polarized, tagged photon beam. and a longitudinally polarized frozen-spin target. The helicity 3/2 cross-section is found to be small and the results for helicity 1/2 agree with predictions from the MAID analysis.
|
|
| 3. |
- Ahrens, J, et al.
(författare)
-
Helicity dependence of the (gamma)over-right-arrow (p)over-right-arrow -> n pi(+) pi(0) reaction in the second resonance region
- 2003
-
Ingår i: Physics Letters. Section B: Nuclear, Elementary Particle and High-Energy Physics. - 0370-2693. ; 551:1-2, s. 49-55
-
Tidskriftsartikel (refereegranskat)abstract
- The helicity dependence of the total cross section for the (γ) over right arrow(p) over right arrownpi(+) pi(0) reaction has been measured for the first time at incident photon energies from 400 to 800 MeV The measurement was performed with the large acceptance detector DAPHNE at the tagged photon beam facility of the MAMI accelerator in Mainz. This channel is found to be excited predominantly when the photon and proton have a parallel spin orientation, due to the intermediate production of the D-13 resonance. (C) 2002 Elsevier Science B.V. All rights reserved.
|
|
| 4. |
- Dutz, H, et al.
(författare)
-
First measurement of the Gerasimov-Drell-Hearn sum rule for H-1 from 0.7 to 1.8 GeV at ELSA
- 2003
-
Ingår i: Physical Review Letters. - 1079-7114. ; 91:19: 192001
-
Tidskriftsartikel (refereegranskat)abstract
- To verify the fundamental Gerasimov-Drell-Hearn (GDH) sum rule for the first time experimentally, we measured the helicity dependent total photoabsorption cross section with circularly polarized real photons and longitudinally polarized nucleons in the photon energy range 0.68-1.82 GeV with the tagged photon facility at ELSA. The experiment was carried out with a 4pi detection system, a circularly polarized tagged photon beam, and a frozen spin polarized proton target. The contribution to the GDH sum rule in this photon energy range is [49.9+/-2.4(stat)+/-2.2(syst)] mub.
|
|
| 5. |
- Rose, Carsten, et al.
(författare)
-
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
- 2003
-
Ingår i: European Journal of Cancer. - 1879-0852. ; 39:16, s. 2318-2327
-
Tidskriftsartikel (refereegranskat)abstract
- It was previously shown that letrozole (Femara(R)) was significantly more potent than anastrozole (Arimidex(R)) in inhibiting aromatase activity in vitro and in inhibiting total body aromatisation in patients with breast cancer. The objective of this study was to compare letrozole (2.5 mg per day) and anastrozole (1 mg per day) as endocrine therapy in postmenopausal women with advanced breast cancer previously treated with an anti-oestrogen. This randomised, multicentre and multinational open-label phase IIIb/IV study enrolled 713 patients. Treatment was for advanced breast cancer that had progressed either during anti-oestrogen therapy or within 12 months of completing that therapy. Patients had tumours that were either positive for oestrogen and/or progesterone receptors (48%) or of unknown receptor status (52%). The primary efficacy endpoint was time to progression (TTP). Secondary endpoints included objective response, duration of response, rate and duration of overall clinical benefit (responses and long-term stable disease), time to treatment failure, and overall survival, as well as general safety. There was no difference between the treatment arms in TTP; median times were the same for both treatments. Letrozole was significantly superior to anastrozole in the overall response rate (ORR) (19.1% versus 12.3%, P=0.013), including in predefined subgroups (receptor status-unknown, and soft-tissue- and viscera-dominant site of disease). There were no significant differences between the treatment arms in the rate of clinical benefit, median duration of response, duration of clinical benefit, time to treatment failure or overall survival. Both agents were well tolerated and there were no significant differences in safety. These results support previous data documenting the greater aromatase-inhibiting activity of letrozole and indicate that advanced breast cancer is more responsive to letrozole than to anastrozole as second-line endocrine therapy. (C) 2003 Elsevier Ltd. All rights reserved.
|
|
| 6. |
|
|
| 7. |
|
|
